Energy·Oil & Gas Refining & Marketing·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.55 | N/A | +1375.63% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.55 | N/A | +1375.63% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in their ability to navigate current market conditions. They are focused on operational improvements and cost management.
Management highlighted strong operational performance despite market challenges.
They emphasized ongoing efforts to improve efficiency and reduce costs.
The strong EPS performance significantly exceeded expectations, leading to a notable stock increase of 30.63%. This suggests investor confidence in Calumet's operational strategies. However, the lack of revenue data and guidance may leave some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BIOCRYST PHARMACEUTI
Mar 4, 2019